Browse
Submit Data
Databases
API
Help

Dataset Information

157 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Small cell lung cancer cell line panel whole proteome analysis

ABSTRACT: We conducted a whole proteome analysis of a panel of human small cell lung cancer cell lines that were either sensitive, moderately sensitive, or insensitive to SQLE inhibition to try and identify proteome signatures of sensititivy

INSTRUMENT(S): Orbitrap Fusion

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Lung Neuroendocrine Cell, Cell Culture

DISEASE(S): Small Cell Carcinoma

SUBMITTER: Sebastian Hayes

LAB HEAD: Sebastian Hayes

PROVIDER: PXD011896 | Pride | 2019-01-09

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Publications

A chemical biology screen identifies a vulnerability of neuroendocrine cancer cells to SQLE inhibition.

Mahoney Christopher E CE Pirman David D Chubukov Victor V Sleger Taryn T Hayes Sebastian S Fan Zi Peng ZP Allen Eric L EL Chen Ying Y Huang Lingling L Liu Meina M Zhang Yingjia Y McDonald Gabrielle G Narayanaswamy Rohini R Choe Sung S Chen Yue Y Gross Stefan S Cianchetta Giovanni G Padyana Anil K AK Murray Stuart S Liu Wei W Marks Kevin M KM Murtie Joshua J Dorsch Marion M Jin Shengfang S Nagaraja Nelamangala N Biller Scott A SA Roddy Thomas T Popovici-Muller Janeta J Smolen Gromoslaw A GA

Nature communications 20190109 1

Aberrant metabolism of cancer cells is well appreciated, but the identification of cancer subsets with specific metabolic vulnerabilities remains challenging. We conducted a chemical biology screen and identified a subset of neuroendocrine tumors displaying a striking pattern of sensitivity to inhibition of the cholesterol biosynthetic pathway enzyme squalene epoxidase (SQLE). Using a variety of orthogonal approaches, we demonstrate that sensitivity to SQLE inhibition results not from cholestero ...[more]

PMID: 30626880

Similar Datasets

Evaluation of NCI-7 Cell Line Panel

Project description:Reference materials are vital to benchmarking the reproducibility of clinical tests and essential for monitoring laboratory performance for clinical proteomics. The reference material utilized for mass spectrometric analysis of the human proteome would ideally contain enough proteins to be suitably representative of the human proteome, as well as exhibit a stable protein composition in different batches of sample regeneration. Previously, The Clinical Proteomic Tumor Analysis Consortium (CPTAC) utilized PDX-derived comparative reference (CompRef) materials for the longitudinal assessment of proteomic performance, however, inherent drawbacks of PDX-derived material has resulted in efforts to identify a new source of CompRef material. In this study, we examined the utility of using a panel of seven cancer cell lines, NCI-7 Cell Line Panel, as a reference material for mass spectrometric analysis of the human proteome. Our results showed that not only is the NCI-7 material suitable for benchmarking laboratory sample preparation methods, but NCI-7 sample generation is highly reproducible at both the global and phosphoprotein levels. In addition, the predicted genomic and experimental coverage of the NCI-7 proteome suggests the NCI-7 material may also have applications as a universal standard proteomic reference.

2018-05-14 | PXD008952 | Pride

Breast cancer cell line panel stimulated with estradiol

Project description:Breast cancer cell line panel stimulated with estradiol

| PRJNA525306 | ENA

Global Proteome Analysis of the NCI-60 Cell Line Panel

Project description:The NCI-60 cell line collection is a very widely used panel for the study of cellular mechanisms of cancer in general and in vitro drug action in particular. It is a model system for the tissue types and genetic diversity of human cancers and has been extensively molecularly characterized. Here, we present a quantitative proteome and kinome profile of the NCI-60 panel covering, in total, 10,350 proteins (including 375 protein kinases) and including a core cancer proteome of 5,578 proteins that were consistently quantified across all tissue types. Bioinformatic analysis revealed strong cell line clusters according to tissue type and disclosed hundreds of differentially regulated proteins representing potential biomarkers for numerous tumor properties. Integration with public transcriptome data showed considerable similarity between mRNA and protein expression. Modeling of proteome and drug-response profiles for 108 FDA-approved drugs identified known and potential protein markers for drug sensitivity and resistance. To enable community access to this unique resource, we incorporated it into a public database for comparative and integrative analysis (http://wzw.tum.de/proteomics/nci60).

2017-03-31 | PXD005940 | Pride

Small non-coding RNA transcriptome of the NCI-60 cell line panel.

Project description: Not available

| S-EPMC5654365 | biostudies-literature

Proteome Analysis of Non-Small Cell Lung Cancer Cell Line Secretomes and Patient Sputum Reveals Biofluid Biomarker Candidates for Cisplatin Response Prediction

Project description:We profiled the secretomes of six NSCLC cell lines with varying IC50-values for cisplatin, using label-free GeLC-MS/MS-based proteomics. Out of a total dataset of 2618 proteins, 304 proteins showed significant differences in expression levels between cisplatin sensitive and insensitive cell lines. Functional data mining revealed that the secretion of typically extracellular factors was associated with a higher sensitivity towards cisplatin, while cisplatin insensitivity correlated with increased secretion of theoretically intra-cellular proteins, in line with enhanced levels of non-conventional secretion in cisplatin insensitive cell lines. Stringent statistical analysis and quantitative filtering yielded 41 top biomarker candidates, many of which could also be detected in NSCLC patient sputum using label-free GeLC-MS/MS-based proteomics. A published gene expression dataset was used to determine which of our top secretome cisplatin response prediction candidates might have predictive value in terms of overall survival in patients that received platinum-based treatment. This analysis yielded two cisplatin sensitivity (UGGT1 and MATN2) and one cisplatin resistance (MAP4) candidates that may serve as potential biomarkers for cisplatin response prediction in NSCLC patients in the future.

2022-02-28 | PXD005830 | Pride

NCI small cell lung cancer cell line panel

Project description:This SuperSeries is composed of the SubSeries listed below.

2016-05-01 | GSE73162 | GEO

The Ludwig Institute for Cancer Research Melbourne Melanoma Cell Line Panel

Project description:Expression profiling of a panel of metastatic melanoma cell lines

2013-02-01 | E-MTAB-1496 | biostudies-arrayexpress

Multi-level characterization of a glioblastoma cell line panel

Project description:Multi-level characterization of a glioblastoma cell line panel

| PRJNA489809 | ENA

Targeted RNA Sequencing of a panel of ovarian cancer cell lines

Project description:Assess the baseline expression of the genes in the Oncology Biomarker Panel across the panel of ovarian and cervical cancer cell lines. This data will then be compared to the sensitivity of the cell lines to DDR inhibitors. The expression data will be correlated with the sensitivity of the cell lines to see whether determinants of sensitivity described in the literature translate. A hierarchy of genes will be determined. It is expected that the cells that are more sensitive to DDR inhibitors will have decreased expression of the genes known to be determinants of sensitivity.

2020-05-21 | GSE150942 | GEO

Global Proteome Analysis of the NCI-60 Cell Line Panel, part 2

2017-03-31 | PXD005942 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data